June 27, 2012 — A novel peptide analogue, teduglutide (Revestive, Nycomed/Takeda), is the first medical treatment recommended for approval by the European Medicines Agency (EMA) for use in adults with ...

In the absence of registry data, it is impossible to know the precise incidence and prevalence of short bowel syndrome in the United States. On the basis of European data, the incidence of total ...

Short Bowel Syndrome (SBS) is a multifaceted condition arising from extensive surgical resection of the small intestine, which leads to impaired nutrient absorption and a heightened risk of ...

Short bowel syndrome is a complex group of diseases caused by the loss (or loss of function) of part of the small and/or large intestine. Patients with short bowel syndrome can’t absorb sufficient ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Stool frequency and consistency improved over 96 weeks ...

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...

FDA orphan drug granted. The Company has already completed a Phase 1 trial of this synthetic glucagon-like peptide (GLP-2) analog. The Food and Drug Administration (FDA) has granted Orphan Drug ...

Gattex (teduglutide), a drug for the treatment of adult short bowel syndrome, has received a recommendation for approval from the FDA’s Gastrointestinal Drugs Advisory Committee, according to a news ...

This new IP supports crofelemer’s global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Apraglutide reduced weekly dependency on parenteral ...